MARKET

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ
0.7391
-0.0171
-2.26%
Opening 14:29 12/06 EST
OPEN
0.7686
PREV CLOSE
0.7562
HIGH
0.7700
LOW
0.7270
VOLUME
132.46K
TURNOVER
0
52 WEEK HIGH
1.390
52 WEEK LOW
0.5000
MARKET CAP
92.61M
P/E (TTM)
-3.1331
1D
5D
1M
3M
1Y
5Y
EU clears up to 1.2 bln euros of aid for cloud computing
NASDAQ · 1d ago
Weekly Report: what happened at ATOS last week (1127-1201)?
Weekly Report · 2d ago
Weekly Report: what happened at ATOS last week (1120-1124)?
Weekly Report · 11/27 10:47
Atossa Therapeutics Announces Full Enrollment Of Phase 2 Karisma-Endoxifen Clinical Trial
Atossa therapeutics has reached full enrollment in the karisma-endoxifen clinical trial. The 240-person study is investigating (z)-endox ifen in premenopausal women with measurable mammographic breast density. Atossa is a clinical stage biopharmaceutical company with a focus on breast cancer.
Benzinga · 11/20 13:31
Weekly Report: what happened at ATOS last week (1113-1117)?
Weekly Report · 11/20 10:45
Atossa Therapeutics’ Strong Financial Position and Promising Clinical Trials Drive Buy Rating: A Focus on Oral Endoxifen Breast Cancer Treatment
TipRanks · 11/15 17:36
Atossa Therapeutics GAAP EPS of -$0.05 beats by $0.02
Atossa therapeutics q3 gaap eps of -$0.05 beats by $0.02. Atossa ended third quarter 2023 with $94.0 million of cash and cash equivalents. The company's gaap revenue for the quarter was -$1.2 million.
Seeking Alpha · 11/13 19:26
Atossa Therapeutics Inc: Current report
Press release · 11/13 14:18
More
About ATOS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines in areas of unmet medical need in oncology with a focus on breast cancer. The Company’s lead drug candidate under development is oral (Z)-endoxifen, which the Company is developing in two settings: one to treat breast cancer by reducing tumor cell activity prior to surgery and another to reduce breast tissue density in women. Its programs under development include (Z)-endoxifen Programs, AT-H201, and other programs. (Z)-endoxifen is an active metabolite of tamoxifen, to treat and prevent breast cancer in high-risk women. It is developing a form of (Z)-endoxifen, which is administered orally for the potential treatment of breast cancer and reduction of breast density. AT-H201 is for lung injury caused by cancer treatments. AT-H201 consists of a combination of two drugs to treat other diseases. Its other programs include Immunotherapy/CAR-T Programs, which is in early stage of development.

Webull offers Atossa Therapeutics Inc stock information, including NASDAQ: ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATOS stock methods without spending real money on the virtual paper trading platform.